



Meta-Analysis Working Group REPORT to GA Chicago June 2017

Chair: Ros Glasspool (SGCTG) Co Chair: Xavier Paoletti (GINECO)

ONGOING TRIALS

Trial disease site and stage (e.g. Ovarian cancer: conservative treatment; Symptom benefit; Endometrial: advanced/recurrent; Rare Tumour: low risk; Cervix: surgical, etc)

Trial Name	Trial Description	# pts enrolled/total	Lead Group/Contact person
SEPOC	<p>Surrogate Endpoints in Ovarian Cancer</p> <p>Pilot project for the MA group</p> <p>Primary objective: to assess surrogate endpoints for OS of</p> <ul style="list-style-type: none"> • Progression free survival defined as per GCIg criteria and by RECIST alone • Overall response using RECIST v1.1 	<p>4 groups have share 8 trials to date: GINECO, MITO, HeCOG and EORTC</p> <p>Data sharing agreement/data extraction in process for a further 8 trials: JGOG, SGCTG, CCTG and 2 individual trials</p> <p>Awaiting Review: MRC, GOG and NSGOG</p>	GINECO/SGCTG Xavier Paoletti

New Proposals:

Secondary Analyses on SEPOC:

3 proposals

- Prognostic value of lymphocytes and other markers of immunology at baseline (J Paul / SGCTG)
- Prognostic value of CA125 summary (Kelim) in patients with paclitaxel intensification regimen (B You / GINECO)
- Predictive value of lymphocytes ratio (J Ethier/ CCTG)

Next steps: The steering committee will meet via t/c Sept to review all proposals from contributing groups

Data –analysis will begin before the end of the year

Aim for primary analysis in time for ASCO 2018

Next Steps

Encourage proposals for new secretariats/projects